Jan van de Winkel, PhD
President and CEO at Genmab
Speaker

Profile

Jan van de Winkel is President and Chief Executive Officer of Genmab, which he co-founded in February 1999. Genmab is a leading international biotechnology company that specializes in the creation and development of innovative and differentiated antibody therapeutics, with the aim of transforming the lives of people with cancer and other serious diseases. Under Dr. van de Winkel’s leadership, Genmab has achieved many key milestones including,

More than 20 key partnerships to create next-generation therapies,
More than 45 investigational new drug applications for antibodies created by Genmab or with Genmab’s technologies, which have led to ~20 investigational medicines currently in clinical development incorporating Genmab’s innovation,
8 approved medicines incorporating Genmab’s innovation, all receiving breakthrough therapy designation or accelerated approval,
Proprietary and partnered pipeline includes over twenty, first-in-class and best-in-class investigational therapies to tackle a variety of cancers.

Dr. van de Winkel has overseen the creation and development of a number of treatments for cancer and other diseases. Genmab is the creator of the following approved antibodies: TIVDAK™ (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate in the U.S., Europe and Japan for the treatment of advanced cervical cancer and the first therapy Genmab has brought to patients (in partnership with Pfizer); EPKINLY (epcoritamab-bysp), the first and only bispecific antibody to treat adults with R/R DLBCL and R/R FL (in partnership with AbbVie); DARZALEX^® (daratumumab, marketed by J&J) a therapy that has redefined the treatment of multiple myeloma. It is the first and only subcutaneous monoclonal antibody targeting CD38 approved for treatment of multiple myeloma and the first and only approved treatment for light-chain (AL) amyloidosis. Additional approved antibodies include: Kesimpta^® (subcutaneous ofatumumab, marketed by Novartis), the first B-cell therapy that can be self-administered by relapsing multiple sclerosis patients at home; TEPEZZA^® (teprotumumab, under agreement with Roche, now owned by Amgen) the first and only FDA-approved medicine for the treatment of thyroid eye disease, RYBREVANT (amivantamab-vmjw, marketed by J&J), the first bispecific antibody approved in the U.S. for lung cancer created using Genmab’s DuoBody^® technology, TECVAYLI (teclistamab) the first bispecific antibody for treatment of relapsed / refractory multiple myeloma, created using Genmab’s DuoBody^®technology, and Talvey™ (talquetamab-tgvs, marketed by J&J), a bispecific antibody for treatment of heavily pre-treated multiple myeloma, created using Genmab’s DuoBody^®technology.